Streptozotocin, when given on consecutive days in subdiabetogenic doses, induces in susceptible mice a progressive loss of B islet cell function leading to hyperglycaemia [1, 2] . The low-dose streptozotocin-induced diabetes has been taken as a model of human Type I (insulin-dependent) diabetes. In both cases lymphocytic infiltration (insulitis) was observed during the early phases of the disease. An impact of viral and immune factors in the pathogenesis has been postulated [3] [4] [5] . Mice can be protected from the disease by immunosuppressive treatment [6] . Low-dose streptozotocin-induced insulitis has been transferred into healthy mice by means of lymphocytes from diabetogenic animals [7] . Whether recipient mice develop hyperglycaemia is still a matter of dispute [7] [8] [9] [10] . As in the human disease, genetic factors seem to be involved in the animal model, i.e. inbred mouse strains differ widely in their susceptibility towards the diabetogenic effect of streptozotocin [11, 12] . In addition, we have shown that the successful transfer of insulitis by lymphocytes depends on a permissive genetic background [13] . This study was designed to investigate whether genes within the major histocompatibility complex (H-2 complex) in mice affect the low-dose streptozotocin-induced diabetes.
Materials and Methods
Male mice of the following five congenic resistant strains: Bt0.A/01a (H-2a), C57BL/10ScSn/01a (H-2b), BlO.D2/n/Ola (H-2d), B10.BR/01a (H-2 k) and BI0.S/01a (H-2~), aged 8-10 weeks, were obtained from OLAC 1976 Ltd, Shaw's Farm, Bicester Oxon, UK. The experimental animals received five doses of streptozotocin (40 mg/kg body weight, Boehringer, Mannheim, FRG) on consecutive days. The compound was injected IP immediately after solution in sodium citrate (0.025 tool/l, pH 4.0), using 0.5 ml per animal. In each strain, 13-26 animals were injected with streptozotocin and 6-12 control mice received injections of buffer alone. All mice were kept on the same standard diet ('ssniff M', Ssniff, Soest, FRG).
Blood of non-fasted mice was drawn from the retro-orbital vein plexus between 0900 and 1100 h. Blood was sampled before starting the experiments and on days 21, 50 and 100 and determined in a Technicon autoanalyzer using the hexokinase method of Boehringer.
All data are expressed as mean + SEM. Statistical significance of differences were determined by Student's t-test for independent samples (two-tailed).
Results
The response of the five congenic mouse strains is compared in Table 1 and Figure 1 . Mice of strain B10.BR (H-U) responded to low-dose streptozotocin treatment 0012-186X/82/0023/0069/$01.00 Table 1 . Corresponding alleles of the H-2 subregions of congenic resistant mouse strains and their response to treatment with streptozotocin and 50 falling to 12 retool/1 on day 100 after streptozotocin treatment). Most of these values were significantly different from those of strain B10.BR (2 p < 0.05 or 0.01, respectively). The lowest blood glucose concentrations following streptozotocin injections were seen in mice of strain B10.S (H-2~). After an initial rise to 11 retool/l, mean blood glucose concentrations fell to approximately 8 mmol/1, which was significantly different from the results seen in the other four strains (2p < 0.01). Also included in Figure I is the area of normoglycaemic values of buffer-treated control animals of all five congenic resistant strains.
The body weight was determined regularly in all experimental animals and no major loss was observed. A few apparently sick animals were seen only in strain B10.D2 and these were eliminated from the study in order not to bias average blood glucose levels.
Discussion
In the experiments presented here an attempt has been made to determine whether genes within the major histocompatibility complex control low-dose streptozotocin-induced diabetes in mice. The comparison of five strains differing only at their H-2 region shows significant differences in the susceptibility towards the diabetogenic action of low-dose streptozotocin. Mice of strain B10.BR (H-2 k) responded with strong and persistent hyperglycaemia and mice of strains C57BL/10 (H-2b), B10.A (H-2 ") and B10.D2 (H-2 d) had significantly lower mean blood glucose levels during the observation period of 100 days. Mice of strain B10.S (H-2 s) did not develop hyperglycaemia except for a transient and moderate increase of blood glucose values.
These data indicate that genes located at the H-2 region of mice affect the diabetic response to low-dose streptozotocin treatment. Different haplotypes of H-2 determine a state of high susceptibility (H-2 k) or a state of resistance (H-2S). It is of interest that strain DBA/2, carrying the H-2 d gene complex on a different genetic background, has turned out to be highly susceptible to lowdose streptozotocin treatment [14] . This observation suggests that genes outside the H-2 region are also involved in the genetic control of this disease. A major influence of non-H-2 genes has been concluded from the comparison of several mouse strains with similar H-2 regions [111.
The susceptibility of mice to the diabetogenic action of low-dose streptozotocin thus appears to be controlled by at least two genes, one within and one outside the major histocompatibility complex. Our results do not allow any conclusion on the mode of action of H-2 genes. Resistance or susceptibility to low-dose streptozotocin may be determined on the level of streptozotocin -B cell interactions, B cell regeneration and/or immunological B cell destruction. We have recently presented evidence that resistance to low-dose streptozotocin treatment is controlled at the level of immunoregulation in mouse strain BALB/c (H-2 d) [12] . Mice of this strain become susceptible to the diabetogenic effect of low-dose streptozotocin after application of low doses of cyclophosphamide. Such a treatment is known to inactivate T-suppressor cells preferentially [15] . Experiments to determine the mechanism of H-2 gene control of low-dose streptozotocin-induced diabetes are in progress.
Our observations relate to findings in other animal models of human Type I diabetes. In the diabetes of mice induced by the M-variant of EMC virus, an influence of either non-H-2 genes [16, 17] and H-2 genes [18] was found, whereas the induction of glucose intolerance after immunization with pancreatic antigens seems to be only H-2 controlled [18] .
